Fairmount Funds Management’s RayzeBio RYZB Stock Holding History
Bought
Maintained
Sold
Fairmount Funds Management's RYZB Position: Q1 2024 in Review
Fairmount Funds Management sold out of RayzeBio (RYZB) in Q1 2024, closing a stake of 1,245,929 shares — an estimated $77.5M sold.
Fairmount Funds Management first reported a position in RYZB in Q3 2023 and held it in 2 quarters. The position peaked at $77.5M in Q4 2023. 0 funds tracked by Wall St. Rank hold RYZB as of Q1 2024.
- Fairmount Funds Management reported no remaining RayzeBio position as of Q1 2024 after selling out during the quarter.
- Fairmount Funds Management sold 1,245,929 RayzeBio shares in Q1 2024, an estimated $77.5M.
- Fairmount Funds Management first reported a position in RayzeBio in Q3 2023 and held it in 2 quarters.
- Fairmount Funds Management's RayzeBio position peaked at $77.5M in Q4 2023.
- 0 funds tracked by Wall St. Rank held RayzeBio as of Q1 2024.
Based on Fairmount Funds Management's 13F filing for Q1 2024, filed 15 May 2024.